The Role for Cardiovascular Remodeling in Cardiovascular Outcomes

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2017 Mar 31

PMID 28357714

Citations 21

Authors

Nishant Krishna Sekaran

Anna Lisa Crowley

Fernanda Rodrigues de Souza

Elmiro Santos Resende

Sunil V Rao

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Ischemic and non-ischemic injury to the heart causes deleterious changes in ventricular size, shape, and function. This adverse remodeling is mediated by neurohormonal and hemodynamic alterations and is reflected in non-invasive measures of left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV). These measures are closely linked to cardiovascular outcomes and have become key surrogate endpoints for evaluating the therapeutic efficacy of contemporary treatments for heart failure with reduced ejection fraction (HFrEF). In this review, we critically evaluate recent published data (2015-2016) from randomized clinical trials (RCTs) and observational studies of HFrEF therapies to assess the role of ventricular remodeling on outcomes.

Recent Findings: These data highlight the benefits of certain guideline-directed medical therapies (GDMT) such as cardiac resynchronization therapy, surgical revascularization, and mechanical circulatory support on remodeling, while revealing the limitations of other therapies-routine mitral valve repair for patients with moderate ischemic mitral regurgitation and adjuncts to percutaneous coronary intervention in patients with ST elevation myocardial infarction (cyclosporine A and bioabsorbable cardiac matrix). The new angiotensin receptor blocker/neprilysn inhibitor, sacubitril/valsartan, demonstrates convincing improvements in clinical outcomes with a study of remodeling parameters to follow; the new cardiac myosin activator, omecamtiv mecarbil, demonstrates improvement in remodeling parameters without a clear early clinical benefit. The concepts and contemporary trials reviewed in this paper reinforce the value of non-invasive measures of ventricular remodeling (LVEF, LVESV, and LVEDV) as important metrics across a range of cardiovascular therapies. Global non-invasive measures of cardiovascular remodeling have roughly paralleled or preceded hard clinical outcomes. Additionally, the capacity for reverse remodeling in HFrEF with GDMT motivates continued research in the fields of implementation science, diagnostic imaging, and gene-based therapeutics.

Citing Articles

MicroRNA-26b inhibits cardiac remodeling after myocardial infarction by targeting ring finger protein 6 expression.

Tang C, Su Q, Zhao H, Sui H, Liang J, Zhu L Arch Med Sci. 2025; 20(6):2009-2021.

PMID: 39967940 PMC: 11831335. DOI: 10.5114/aoms/130649.

Interleukin-5 alleviates cardiac remodelling via the STAT3 pathway in angiotensin II-infused mice.

Shen C, Wu N, Chen X, Peng J, Feng M, Wang J J Cell Mol Med. 2024; 28(13):e18493.

PMID: 38963241 PMC: 11223166. DOI: 10.1111/jcmm.18493.

Different Continuous Training Intensities Improve Echocardiographic Parameters, Quality of Life, and Functional Capacity in Heart Failure Patients with Reduced Ejection Fraction.

Abdeen H, Helmy Z, Elnaggar M, Aldhahi M, Taha M, Marques-Sule E Int J Gen Med. 2023; 16:3933-3945.

PMID: 37670928 PMC: 10475351. DOI: 10.2147/IJGM.S420933.

The Rare Condition of Left Ventricular Non-Compaction and Reverse Remodeling.

Bustea C, Bungau A, Tit D, Iovanovici D, Toma M, Bungau S Life (Basel). 2023; 13(6).

PMID: 37374101 PMC: 10305066. DOI: 10.3390/life13061318.

Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest.

Palazzuoli A, Correale M, Iacoviello M, Gronda E J Clin Med. 2023; 12(2).

PMID: 36675622 PMC: 9867046. DOI: 10.3390/jcm12020693.

References

Voigt J, Pedrizzetti G, Lysyansky P, Marwick T, Houle H, Baumann R . Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr. 2015; 28(2):183-93. DOI: 10.1016/j.echo.2014.11.003. View

Guder G, Stork S, Gelbrich G, Brenner S, Deubner N, Morbach C . Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling. Eur J Heart Fail. 2015; 17(4):442-52. DOI: 10.1002/ejhf.252. View

Teerlink J, Felker G, McMurray J, Ponikowski P, Metra M, Filippatos G . Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol. 2016; 67(12):1444-1455. DOI: 10.1016/j.jacc.2016.01.031. View

Mollova M, Bersell K, Walsh S, Savla J, Das L, Park S . Cardiomyocyte proliferation contributes to heart growth in young humans. Proc Natl Acad Sci U S A. 2013; 110(4):1446-51. PMC: 3557060. DOI: 10.1073/pnas.1214608110. View

Khouri M, Peshock R, Ayers C, de Lemos J, Drazner M . A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study. Circ Cardiovasc Imaging. 2010; 3(2):164-71. DOI: 10.1161/CIRCIMAGING.109.883652. View

Velazquez E, Lee K, Jones R, Al-Khalidi H, Hill J, Panza J . Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016; 374(16):1511-20. PMC: 4938005. DOI: 10.1056/NEJMoa1602001. View

Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G . Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014; 383(9932):1933-43. PMC: 4330973. DOI: 10.1016/S0140-6736(14)60107-0. View

White H, Norris R, Brown M, Brandt P, Whitlock R, Wild C . Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987; 76(1):44-51. DOI: 10.1161/01.cir.76.1.44. View

Cohn J, Ferrari R, Sharpe N . Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000; 35(3):569-82. DOI: 10.1016/s0735-1097(99)00630-0. View

10.

Sze E, Daubert J . Left Bundle Branch Block: Is it "Unsafe at Any Speed"?. JACC Heart Fail. 2016; 4(11):904-906. DOI: 10.1016/j.jchf.2016.09.004. View

11.

Solomon S, Skali H, Anavekar N, Bourgoun M, Barvik S, Ghali J . Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005; 111(25):3411-9. DOI: 10.1161/CIRCULATIONAHA.104.508093. View

12.

Hoit B . Left Atrial Remodeling: More Than Just Left Atrial Enlargement. Circ Cardiovasc Imaging. 2017; 10(2). DOI: 10.1161/CIRCIMAGING.117.006036. View

13.

Ottani F, Latini R, Staszewsky L, La Vecchia L, Locuratolo N, Sicuro M . Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial. J Am Coll Cardiol. 2016; 67(4):365-374. DOI: 10.1016/j.jacc.2015.10.081. View

14.

Gold M, Daubert C, Abraham W, Ghio S, St John Sutton M, Hudnall J . The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2014; 12(3):524-530. PMC: 4390984. DOI: 10.1016/j.hrthm.2014.11.014. View

15.

Oh J, Pellikka P, Panza J, Biernat J, Attisano T, Manahan B . Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. J Am Soc Echocardiogr. 2012; 25(3):327-36. PMC: 3310914. DOI: 10.1016/j.echo.2011.12.002. View

16.

Bergmann O, Zdunek S, Felker A, Salehpour M, Alkass K, Bernard S . Dynamics of Cell Generation and Turnover in the Human Heart. Cell. 2015; 161(7):1566-75. DOI: 10.1016/j.cell.2015.05.026. View

17.

Verma A, Meris A, Skali H, Ghali J, Arnold J, Bourgoun M . Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging. 2009; 1(5):582-91. DOI: 10.1016/j.jcmg.2008.05.012. View

18.

Hundley W, Bluemke D, Finn J, Flamm S, Fogel M, Friedrich M . ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010; 55(23):2614-62. PMC: 3042771. DOI: 10.1016/j.jacc.2009.11.011. View

19.

Lumens J, Prinzen F, Delhaas T . Longitudinal Strain: "Think Globally, Track Locally". JACC Cardiovasc Imaging. 2015; 8(12):1360-1363. DOI: 10.1016/j.jcmg.2015.08.014. View

20.

Goldstein D, Moskowitz A, Gelijns A, Ailawadi G, Parides M, Perrault L . Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med. 2015; 374(4):344-53. PMC: 4908819. DOI: 10.1056/NEJMoa1512913. View